NCCN Guidelines for Patients® | Lung Cancer - Non-Small Cell Lung Cancer

112 NCCN Guidelines for Patients ® : Lung Cancer – Non-Small Cell, 2018 Index Index 2 nd opinion 98 ablation 43, 58, 62, 78–79 ALK 36–38, 49–52, 55, 85 blood test 22, 30, 39 biomarker testing 36, 39 biopsy 15–20, 30, 32–37, 39 bronchoscopy 19, 32, 34, 39 cancer stage 26–27, 33, 39, 62, 67 chemoradiation 60–61, 66–69, 72–77, 81, 83 chemotherapy 47–49, 54–55, 57–58, 60–61, 63, 66–69, 72–75, 78–79, 81, 84–91 clinical trial 38, 55, 57–58, 88, 91, 95 complementary and alternative medicine (CAM) 55 imaging 13, 15–16, 19–20, 22, 30–31, 34, 39, 44, 73, 98 immunotherapy 56–58 low-dose computed tomography (LDCT) 16, 39, 64, 70, 77, 80 medical history 29, 39, 64, 70, 76–77, 80 NCCN Member Institutions 111 NCCN Panel Members 110 pathology report 36, 94, 98 performance status 29, 84–86, 88–91 physical exam 29, 64, 70, 76–77, 80 primary tumor 10, 22–25, 36, 60, 62–81 pulmonary function test 33, 39 radiation therapy 14, 33, 39, 43–46, 58, 60–64, 66–67, 70, 75–76, 78–83 risk factors 13, 16, 112 side effect 33, 43, 46, 48–55, 57–58 superior sulcus tumor 31, 39, 66, 68–69, 73–74 surgery 19–20, 22, 30, 32–36, 39, 41–43, 45, 58, 60–63, 66–69, 72–76, 78–79, 81, 83 survivorship plan 63–64, 66–70, 74, 76–77, 79–81 supportive care 43, 83, 88–91 targeted therapy 49–55, 58, 84–85, 91

RkJQdWJsaXNoZXIy MTE3MTE1